Cargando…

Olfactory Neuroblastoma: The Adjunctive Role of Somatostatin Agonists After Surgery

Clinical Case: A 54 years old woman who had a right-sided nasal obstruction, rhinorrhea, and sometimes purulent discharge in 2016. In 2002 she had hyperthyroidism by Graves disease and treated for two years with remission after that. The examination of the nose revealed a dark red bleeding mass fill...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toral, Fernando Pazos, Martino, Maria, Duro, David Lobo, Rodriguez, Isabel Martinez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265962/ http://dx.doi.org/10.1210/jendso/bvab048.1213

Ejemplares similares

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands
por: Gadelha, Monica R, et al.
Publicado: (2023)

SAT628 Effect Of Hepatic Impairment On The Pharmacokinetics, Safety, And Tolerability Of Oral Paltusotine, A Non-peptide, Selective Somatostatin Receptor Subtype 2 Agonist
por: Luo, Rosa, et al.
Publicado: (2023)

MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey
por: Tanaka, Hirotaka, et al.
Publicado: (2019)

FRI296 Somatostatin Receptor 5 Staining In Prolactinomas
por: Mehta, Sonal, et al.
Publicado: (2023)

MON-464 Non-Clinical Profiling of ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, to Support Studies in Humans
por: Komagata, Tatsuya, et al.
Publicado: (2019)

MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas
por: Soto, Alfonso, et al.
Publicado: (2019)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

SAT-430 A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of ONO-5788: A Novel Oral Small Molecule Somatostatin Receptor Type-2 Agonist
por: Kaviya, Arpeat, et al.
Publicado: (2019)

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
por: Zhou, Cuiqi, et al.
Publicado: (2019)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

A Rare Case of Thyrotropin Secreting Pituitary Macroadenoma Primarily Treated With Somatostatin Analogue
por: Elsheikh, Arwa Mahmoud, et al.
Publicado: (2021)

SAT605 Growth Hormone Action In Somatostatin Neurons Regulates Anxiety And Fear Memory
por: dos Santos, Willian O, et al.
Publicado: (2023)

OR01-05 Growth Hormone Action In Somatostatin Neurons Regulates Anxiety And Fear Memory
por: dos Santos, Willian O, et al.
Publicado: (2023)

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

THU063 Somatostatin Analog Neoadjuvant Treatment Before Endoscopic Surgery For Growth-Hormone Producing Pituitary Adenomas Invading The Cavernous Sinus: Case Series, Systematic Literature Review And Meta-analysis
por: Rapoport, Benjamin, et al.
Publicado: (2023)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023)

OR06-02 TBR-760, a Chimeric Somatostatin-Dopamine Compound, Arrests Aggressive Non-Functioning Pituitary Adenoma Growth In Vivo
por: Halem, Heather A, et al.
Publicado: (2020)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

SAT-439 Impact on Health Care Resources: A Comparison of Costs Following Treatment with Pegvisomant and Somatostatin Analogues Using Optum Claims Database
por: Kelepouris, Nicky, et al.
Publicado: (2019)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Safety and Efficacy of Switching Injected Peptide Long-Acting Somatostatin Receptor Ligands to Once Daily Oral Paltusotine: ACROBAT Edge Phase 2 Study
por: Gadelha, Monica R, et al.
Publicado: (2021)

RF01 | PMON168 Hedgehog-Induced Somatostatin Receptor Expression is Inhibited by the Activation of the Glucocorticoid Receptor Signaling Pathway in Human Pituitary Adenoma Organoids
por: Zavros, Yana, et al.
Publicado: (2022)

THU064 Clinical, Radiological Characteristics And Response To Somatostatin Analogues Of Acromegaly Patients With Different Patterns Of Growth Hormone Response After Oral Glucose Load
por: Godlewska, Magdalena, et al.
Publicado: (2023)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

Olfactory Performance in Youth With Full and Subthreshold Avoidant/Restrictive Food Intake Disorder
por: Stull, Madeline Rogers, et al.
Publicado: (2021)

LBMON140 Central Diabetes Insipidus Manifesting After Vasopressin Withdrawal In A Critically Ill Patient
por: Patel, Toral, et al.
Publicado: (2022)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

SAT-313 Synaptojanin 2 Binding Protein Is Required for Efficient Somatostatin Receptor 2A Phosphorylation by G Protein Coupled Receptor Kinases and Signaling to the ERK/MAPK Pathway
por: Carr, Heather S, et al.
Publicado: (2020)

THU055 The Acro-TIME Score: A New Clinical, Pathological And Immune Integrative Approach To Early Identify Acromegaly Patients Resistant To Treatment With First Generation Somatostatin Ligands
por: Chiloiro, Sabrina, et al.
Publicado: (2023)

OR06-2 Kisspeptin Enhances Brain Processing of Olfactory and Visual Cues of Attraction in Men
por: Yang, Lisa, et al.
Publicado: (2019)

SUN-303 Effects of Open-Label, Adjunctive Ganaxalone Treatment on Resistant Depression in Postmenopausal Women: A Pilot Study
por: Dichtel, Laura E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_shtitls18c962fjg04kb25o4k8